Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma

10.1182/blood-2013-12-546374

Saved in:
Bibliographic Details
Main Authors: San-Miguel, J, Bladé, J, Shpilberg, O, Grosicki, S, Maloisel, F, Min, C.-K, Zarzuela, M.P, Robak, T, Prasad, S.V.S.S, Goh, Y.T, Laubach, J, Spencer, A, Mateos, M.-V, Palumbo, A, Puchalski, T, Reddy, M, Uhlar, C, Qin, X, Van De Velde, H, Xie, H, Orlowski, R.Z
Other Authors: DUKE-NUS MEDICAL SCHOOL
Format: Article
Published: American Society of Hematology 2020
Subjects:
Online Access:https://scholarbank.nus.edu.sg/handle/10635/183894
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore
Description
Summary:10.1182/blood-2013-12-546374